Butterfly's $74 million Midjourney license rests on a scanner with no FDA clearance and no AI
Butterfly Network's chip-licensing arm just posted a record quarter and its first commercial partner. Its largest licensee is a wellness scanner with no FDA clearance, no AI, and a 2028 roadmap that ends at its own silicon.
Vincent Jiang · 3 min read
A bath, a ring of chips, a 20-minute wait
Midjourney's first hardware product lowers a person into warm water and passes them through a ring of 40 ultrasound chips, every one of them made by Butterfly Network 12. The pitch is a full-body 3D scan in 60 seconds, "dolphins using echolocation" for humans 12. The prototype that exists takes about 20 minutes, has scanned roughly a dozen people, and, by founder David Holz's own account, carries no AI in its imaging pipeline yet 13.
The licensor collects either way
Butterfly put the deal in a Form 8-K on 17 November 2025: up to $74 million in payments over five years, on terms reported at $15 million upfront plus $10 million a year 34. The cash is already landing. Q2 2026 revenue hit a record $32.6 million, up 39 percent, gross margin rose to 71.4 percent from 63.7, and Butterfly said US growth came primarily from Embedded licensing, Midjourney included, before it raised full-year guidance to $119 million to $123 million 5.
Butterfly's revenue hit a record $32.6M the quarter Midjourney license money arrived
Data
| Quarterly revenue | |
|---|---|
| Q3 '23 | $15.42M |
| Q4 '23 | $16.52M |
| Q1 '24 | $17.66M |
| Q2 '24 | $21.49M |
| Q3 '24 | $20.56M |
| Q4 '24 | $22.35M |
| Q1 '25 | $21.23M |
| Q2 '25 | $23.38M |
| Q3 '25 | $21.49M |
| Q4 '25 | $31.51M |
| Q1 '26 | $26.53M |
| Q2 '26 | $32.61M |
Wellness by design, not by accident
The scanner sells "body composition maps," a wellness label that keeps it outside FDA diagnostic clearance for now 123. William Blair analyst Andrew Brackmann named the open questions the same week: how fast diagnostic clearance could come, who reimburses a scan, and whether routine whole-body scanning has shown any utility at all 7. Reviews of whole-body MRI screening find incidental findings in 20 to 40 percent of scans, and only 5 to 15 percent of those need treatment 3.
The chip is earning elsewhere
On 1 October, Mendaera's FDA-cleared Focalist robot became the first Butterfly Embedded partner to reach the market, running a customized iQ3 probe 8. Embedded revenue reached $10.8 million in Q2, up 439 percent year over year, company-reported 9. Needham opened coverage on 22 September at Buy with a $10 target, and the stock jumped 22 percent to $9.93; it traded at $8.93 on 1 October 10119.
The 2028 footnote
Midjourney's roadmap has a third-generation scanner in 2028 running silicon of its own design rather than Butterfly's licensed chips 3. Butterfly's own release says future generations will use "substantially more" modules 4. Butterfly is being paid $74 million to supply a customer whose roadmap ends with supplying itself. Meanwhile officer Megan Carlson filed her fourth Form 144 since July on 2 October, 10,114 shares for $88,447.94, taking her notices to about 134,000 shares and $1.06 million, most of it covering tax on vesting 12.
What decides it
Three readings settle the argument: the body count through the scanner, Q3 revenue against a $26 million to $30 million guide 5, and the next 8-K milestone from Midjourney. A dozen bodies is a demo. Ten thousand is a business.
Deepdive
AI-generated from this story and its cited sources. Not investment advice.


